Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts

Eli Lilly and Co (NYSE:LLY)’s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target’s...